FTC approves Actavis/Warner Chilcott with drug rights divestments
Monday, 30 September 2013 (8 months ago)
The US Federal Trade Commission has approved Actavis’s US$8.5 billion acquisition of Irish rival Warner Chilcott on condition it sells the rights to four generic drugs.
Premium Subscription required to view this article
This content can only be accessed by Premium subscribers.
This content is part of the GCR archive and can only be accessed by subscribers with a Premium Subscription.
If you are a subscriber, please login: